Darren R Veach

List of Publications by Year
in descending order

55 papers	4,551 citations	201385 27 h-index	155451 55 g-index
59 all docs	59 docs citations	59 times ranked	6021 citing authors

#	Article	IF	Citations
1	Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase. Cell, 2003, 112, 859-871.	13.5	762
2	Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Research, 2002, 62, 4236-43.	0.4	684
3	Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. Journal of Clinical Investigation, 2007, 117, 3846-3856.	3.9	574
4	L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. International Journal of Cancer, 2007, 121, 257-264.	2.3	236
5	Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nature Medicine, 2005, 11, 731-739.	15.2	207
6	Gleevec inhibits Â-amyloid production but not Notch cleavage. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12444-12449.	3.3	183
7	Sorafenib Inhibits the Imatinib-Resistant KIT T670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2007, 13, 4874-4881.	3.2	144
8	Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Research, 2002, 62, 4244-55.	0.4	131
9	Two Distinct Phosphorylation Pathways Have Additive Effects on Abl Family Kinase Activation. Molecular and Cellular Biology, 2003, 23, 3884-3896.	1.1	129
10	Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7444-7449.	3.3	121
11	EnteropathogenicEscherichia coliUse Redundant Tyrosine Kinases to Form Actin Pedestals. Molecular Biology of the Cell, 2004, 15, 3520-3529.	0.9	106
12	Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9244-9249.	3.3	104
13	Positron Emission Tomography/Computed Tomographyâ€"Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2018, 4, 217.	3.4	93
14	Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring KITAY502-3ins Mutation: An In vitro Mutagenesis Screen for Drug Resistance. Clinical Cancer Research, 2009, 15, 6862-6870.	3.2	86
15	A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood, 2005, 105, 1652-1659.	0.6	85
16	Caenorhabditis elegans ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation. Nature Genetics, 2004, 36, 906-912.	9.4	74
17	PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood, 2005, 105, 3995-4003.	0.6	66
18	Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. Cancer Research, 2003, 63, 6395-404.	0.4	54

#	Article	IF	Citations
19	Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells. Proteomics, 2006, 6, 4554-4564.	1.3	48
20	Increased KIT Inhibition Enhances Therapeutic Efficacy in Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2014, 20, 2350-2362.	3.2	44
21	Synthesis and Biological Evaluation of a Fluorine-18 Derivative of Dasatinib. Journal of Medicinal Chemistry, 2007, 50, 5853-5857.	2.9	38
22	Fluorine-labeled Dasatinib Nanoformulations as Targeted Molecular Imaging Probes in a PDGFB-driven Murine Glioblastoma Model. Neoplasia, 2012, 14, 1132-IN8.	2.3	37
23	Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nature Communications, 2018, 9, 1629.	5.8	37
24	Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate. Leukemia, 2004, 18, 1352-1356.	3.3	35
25	Imatinib Upregulates Compensatory Integrin Signaling in a Mouse Model of Gastrointestinal Stromal Tumor and Is More Effective When Combined with Dasatinib. Molecular Cancer Research, 2010, 8, 1271-1283.	1.5	34
26	Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E8448-E8457.	3.3	34
27	Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. EJNMMI Research, 2016, 6, 7.	1.1	32
28	Fluorescent monitoring of kinase activity in real time: development of a robust fluorescence-based assay for Abl tyrosine kinase activity. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 3091-3094.	1.0	28
29	Imatinib resistance and microcytic erythrocytosis in a Kit ^{V558Î”;T669I/+} gatekeeper-mutant mouse model of gastrointestinal stromal tumor. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2276-83.	3.3	26
30	Alpha radioimmunotherapy using ²²⁵Ac-proteus-DOTA for solid tumors - safety at curative doses. Theranostics, 2020, 10, 11359-11375.	4.6	26
31	Remodeling the Vascular Microenvironment of Glioblastoma with Î±-Particles. Journal of Nuclear Medicine, 2016, 57, 1771-1777.	2.8	25
32	Internalization of secreted antigenâ€“targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. Science Translational Medicine, 2016, 8, 367ra167.	5.8	23
33	Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer. Clinical Cancer Research, 2019, 25, 881-891.	3.2	21
34	A solid-phase Bcr-Abl kinase assay in 96-well hydrogel plates. Analytical Biochemistry, 2008, 375, 18-26.	1.1	20
35	A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy. Clinical Cancer Research, 2021, 27, 532-541.	3.2	19
36	In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME). Oncotarget, 2017, 8, 65917-65931.	0.8	17

#	Article	IF	Citations
37	A magnetic bead-based protein kinase assay with dual detection techniques. Analytical Biochemistry, 2011, 408, 5-11.	1.1	16
38	Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptorâ€“Axis Imaging. Journal of Nuclear Medicine, 2016, 57, 73S-78S.	2.8	16
39	An N-Acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic-Index DOTA-Hapten Pretargeted Radioimmunotherapy. Bioconjugate Chemistry, 2020, 31, 501-506.	1.8	16
40	Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted Î±-particle therapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 15172-15181.	3.3	16
41	Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors. Nuclear Medicine and Biology, 2005, 32, 313-321.	0.3	14
42	PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates. Clinical Cancer Research, 2021, 27, 2050-2060.	3.2	13
43	Structureâ€“activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: Toward selective Abl inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6872-6876.	1.0	12
44	DNA photocleavage and biological activity of a pyrene dihydrodioxin. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 2173-2176.	1.0	11
45	Dosimetry of 18F-Labeled Tyrosine Kinase Inhibitor SKI-249380, a Dasatinib-Tracer for PET Imaging. Molecular Imaging and Biology, 2012, 14, 25-31.	1.3	10
46	¹²⁴I-Iodopyridopyrimidinone for PET of Abl Kinaseâ€“Expressing Tumors In Vivo. Journal of Nuclear Medicine, 2010, 51, 121-129.	2.8	9
47	Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications. Bioconjugate Chemistry, 2021, 32, 649-654.	1.8	6
48	A Cell-Based Screening Method for Resistance of Bcr-Abl Positive Leukemia Identifies the Mutation Pattern for an Alternative Abl Kinase Inhibitor.. Blood, 2004, 104, 558-558.	0.6	6
49	First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET. Journal of Nuclear Medicine, 2020, 61, 1580-1587.	2.8	5
50	Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis. Molecular Cancer Therapeutics, 2022, 21, 125-137.	1.9	5
51	Cell Treatment and Lysis in 96-Well Filter-Bottom Plates for Screening Bcr-Abl Activity and Inhibition in Whole-Cell Extracts. Journal of Biomolecular Screening, 2010, 15, 434-440.	2.6	4
52	ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts. Molecular Pharmaceutics, 2018, 15, 2133-2141.	2.3	4
53	A fluorine-labeled methotrexate as a probe for monitoring tumor antifolate pharmacokinetics: synthesis, in vitro cytotoxicity, and pilot in vivo 19F magnetic resonance spectra. Molecular Cancer Therapeutics, 2003, 2, 933-9.	1.9	3
54	BCR-ABL Kinase Dynamics and Drug Resistance.. Blood, 2005, 106, 1996-1996.	0.6	1

#	Article	IF	Citations
55	Abstract LB-299: F-dasatinib inhibits glioma cell proliferation and alters expression of PDGFR signaling pathway intermediates in PDGFR-overexpressing glioma models. , 2010, , .		0